These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Respiratory syncytial virus: how, why and what to do. Rodriguez R; Ramilo O J Infect; 2014 Jan; 68 Suppl 1():S115-8. PubMed ID: 24171820 [TBL] [Abstract][Full Text] [Related]
4. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Detalle L; Stohr T; Palomo C; Piedra PA; Gilbert BE; Mas V; Millar A; Power UF; Stortelers C; Allosery K; Melero JA; Depla E Antimicrob Agents Chemother; 2016 Jan; 60(1):6-13. PubMed ID: 26438495 [TBL] [Abstract][Full Text] [Related]
5. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia]. Aliamovskaia GA; Keshinian ES Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423 [TBL] [Abstract][Full Text] [Related]
14. Comparison of BD Directigen EZ RSV and Binax NOW RSV tests for rapid detection of respiratory syncytial virus from nasopharyngeal aspirates in a pediatric population. Selvarangan R; Abel D; Hamilton M Diagn Microbiol Infect Dis; 2008 Oct; 62(2):157-61. PubMed ID: 18597969 [TBL] [Abstract][Full Text] [Related]
15. Prevention of respiratory syncytial virus infection among Puerto Rican infants. Winchester L; García L; García I; Concepción CB P R Health Sci J; 2002 Sep; 21(3):191-3. PubMed ID: 12243108 [TBL] [Abstract][Full Text] [Related]
16. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related]
17. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Onuzo OC Cardiol Young; 2004 Aug; 14(4):466-7; author reply 467-9. PubMed ID: 15680062 [No Abstract] [Full Text] [Related]
18. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988 [TBL] [Abstract][Full Text] [Related]
19. Respiratory syncytial virus: different criteria for palivizumab use in different areas? Mitchell I South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741 [No Abstract] [Full Text] [Related]
20. From chimpanzee coryza to palivizumab: changing times for respiratory syncytial virus. Ogra PL Pediatr Infect Dis J; 2000 Aug; 19(8):774-9; discussion 811-3. PubMed ID: 10959757 [No Abstract] [Full Text] [Related] [Next] [New Search]